Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
SwitzerlandIPO:
18 May 2020Website:
http://www.adctherapeutics.comNext earnings report:
08 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 20:36:03 GMTDividend
Analysts recommendations
Institutional Ownership
ADCT Latest News
Fundamentally, biotech stocks to buy operate on a clear and unavoidable narrative: wealth means nothing without health. You hear various stories about extremely wealthy tycoons throwing all kinds of money, not just for lifesaving procedures but in more superficial efforts such as maintaining youth and vitality.
ADC Therapeutics SA (NYSE: ADCT) has revealed that Ameet Mallik, the Chief Executive Officer, will be taking part in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on May 20, 2024 at 2:00 p.m. ET.
ADC Therapeutics SA (ADCT) reported a quarterly loss of $0.56 per share, which was in line with the Zacks Consensus Estimate. This is an improvement from the loss of $0.74 per share reported in the same quarter last year.
ADC Therapeutics SA (ADCT) came out with a quarterly loss of $1.03 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.30 per share a year ago.
ADC Therapeutics SA (ADCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
With patience, some of the most undervalued biotech stocks can create massive wealth. Look at ACADIA Pharmaceuticals (NASDAQ: ACAD ), for example.
January's payrolls report shows 353,000 jobs
ADC Therapeutics (ADCT) surges after it provides business updates that highlight the company's progress with its pipeline. Multiple data readouts are expected throughout this year.
Here is how ADC Therapeutics SA (ADCT) and CytomX Therapeutics (CTMX) have performed compared to their sector so far this year.
The JPMorgan Healthcare Conference was likely just the beginning of another year of heightened interest and investments in ADC cancer drugs.
- 1(current)
What type of business is ADC Therapeutics SA?
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
What sector is ADC Therapeutics SA in?
ADC Therapeutics SA is in the Healthcare sector
What industry is ADC Therapeutics SA in?
ADC Therapeutics SA is in the Biotechnology industry
What country is ADC Therapeutics SA from?
ADC Therapeutics SA is headquartered in Switzerland
When did ADC Therapeutics SA go public?
ADC Therapeutics SA initial public offering (IPO) was on 18 May 2020
What is ADC Therapeutics SA website?
https://www.adctherapeutics.com
Is ADC Therapeutics SA in the S&P 500?
No, ADC Therapeutics SA is not included in the S&P 500 index
Is ADC Therapeutics SA in the NASDAQ 100?
No, ADC Therapeutics SA is not included in the NASDAQ 100 index
Is ADC Therapeutics SA in the Dow Jones?
No, ADC Therapeutics SA is not included in the Dow Jones index
When does ADC Therapeutics SA report earnings?
The next expected earnings date for ADC Therapeutics SA is 08 August 2024